Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,471 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Testing Clear all
Completed Not applicable Interventional

Multi-Center Study Comparing Efficacy and Safety of Frequently Modified Insulin Therapy

NCT02424500
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypoglycemia
Interventions
d-Nav, Blood Glucose Monitoring System
Device
Lead sponsor
Hygieia Research LLC
Other
Eligibility
21 Years to 70 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Not applicable Interventional

Development and Preliminary Testing of a "Papageno"-Story Interview Intervention- Aim 3

NCT06842667
View directory record Official record
Conditions
Suicide Prevention
Interventions
Papageno video, Control video
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 24 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients

NCT03459287
View directory record Official record
Conditions
Anemia
Interventions
INTERCEPT, Control
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
11 Years and older
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Terminated Phase 1 Interventional Results available

Insulin Tolerance Test Study in Patients With Type 1 Diabetes

NCT04026750
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Pitolisant
Drug
Lead sponsor
High Point Clinical Trials Center
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude

NCT01794078
View directory record Official record
Conditions
Acute Mountain Sickness and Fatigue
Interventions
Aminophylline 400 mg, Ambrisentan 5 mg, Placebo
Drug · Other
Lead sponsor
Robert J Noveck, M.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Injections of LY3074828 in Healthy Participants

NCT03886948
View directory record Official record
Conditions
Healthy
Interventions
LY3074828, Pre-filled syringe (PFS), Autoinjector (AI)
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

NCT03363893
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
CT7001, Fulvestrant
Drug
Lead sponsor
Carrick Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
12
States / cities
Tucson, Arizona • Beverly Hills, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Not applicable Interventional Results available

Medtronic Minimed Overnight Closed-Loop System

NCT01881009
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Autoimmune Diabetes, Juvenile-Onset Diabetes, Diabetes, Mellitus, Type 1
Interventions
Hybrid Closed-loop System, Sensor-augmented pump
Device
Lead sponsor
Bruce A. Buckingham
Other
Eligibility
10 Years to 35 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature

NCT01497938
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature, Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Little Rock, Arkansas • Escondido, California • San Mateo, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Oct 30, 2026, 6:07 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

NCT06581406
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
RP2, Ipilimumab, Nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
Not listed
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Active, not recruiting No phase listed Observational

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

NCT06162585
View directory record Official record
Conditions
Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions
Gene Therapy product-MCO-010
Biological
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

NCT03861234
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
BI 836880
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • New York, New York • Eugene, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 30, 2026, 6:07 AM EDT
Recruiting Not applicable Interventional

A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal Fistulas

NCT05641844
View directory record Official record
Conditions
Anal Fistula
Interventions
RD2 Ver.02, Saline
Device · Other
Lead sponsor
RedDress Ltd.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Weston, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 30, 2026, 6:07 AM EDT
Suspended Not applicable Interventional

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

NCT06391099
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Best Practice, Biospecimen Collection, Computed Tomography, Dietary Intervention, Educational Activity, Glucose Measurement, Ketone Measurement, Questionnaire Administration
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety

NCT04050800
View directory record Official record
Conditions
Neuro-Degenerative Disease
Interventions
Carbon 11 Butanol
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

NCT04077879
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASP1617, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Not applicable Interventional

Is There a Digital Divide in Chronic Kidney Disease (CKD)?

NCT03067779
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
mHealth Tool
Other
Lead sponsor
Duke University
Other
Eligibility
45 Years to 79 Years
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Baltimore, Maryland • Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis

NCT02230696
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray, Placebo nasal spray
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 65 Years
Enrollment
951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
30
States / cities
Stockbridge, Georgia • Louisville, Kentucky • Baltimore, Maryland + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 1 Interventional

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01787474
View directory record Official record
Conditions
Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Cytarabine, Filgrastim, Filgrastim-sndz, Fludarabine Phosphate, Laboratory Biomarker Analysis, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

NCT04530110
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
32
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

NCT02243189
View directory record Official record
Conditions
Healthy, Asthma
Interventions
JNJ-43260295, Placebo, Nasal Allergen Challenge
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 30, 2026, 6:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

This Study Evaluates Skin Response Following Application of a Collagen-based Material in Healthy Adult Volunteers Using a Standardized Skin Prick Test. Skin Responses Will be Assessed at Multiple Time Points Following Application, and the Study is Intended to Evaluate Dermal Safety.

NCT07473674
View directory record Official record
Conditions
Healthy Adult
Interventions
Collagen Matrix Skin Prick Test Device
Device
Lead sponsor
SerenaGroup, Inc.
Network
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Active, not recruiting Phase 3 Interventional

Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients

NCT04188418
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Fentanyl Citrate Buccal Tablet, Morphine, Physical Performance Testing, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 30, 2026, 6:07 AM EDT
Withdrawn Phase 2 Interventional

SOM230 Ectopic ACTH-producing Tumors

NCT02780882
View directory record Official record
Conditions
Ectopic ACTH Syndrome
Interventions
Pasireotide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 30, 2026, 6:07 AM EDT